{"name":"Emalex Biosciences Inc.","slug":"emalex-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPQUNQMnM0TER5dUl1V2RtanRhNzNWZzhwTExmN1c1Zjh5eUJEWGtOMWFoSGd4ckp5SEc0bk5HRjlDQU5BUFphcms4M0NYUkU2R2MxVVlhZmtCc3RlYjNySkVKNU53V1Y4VGl5bUJfaWVKUlA1MEN1NlZBYWRicGNJVmtXaEQ5Nk1SZnRkN0kwRQ?oc=5","date":"2025-03-11","type":"regulatory","source":"Pharma Voice","summary":"The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep - Pharma Voice","headline":"The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3QmRpYWZteUZYVVlUVXlHa0VLX0lIeHZfWm5ZNU5tMnFHem10Z0JidzRPX1RwLVBFQ0VQbVhjZjhCdHVhYTlqZXBNQThjeFp6U2dpQkhfUFpWaTc0ekRj?oc=5","date":"2025-03-08","type":"regulatory","source":"The Pharma Letter","summary":"Emalex Biosciences - The Pharma Letter","headline":"Emalex Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxOdGVFLTlnM2pwZGVyTk1WaWxwSFR2dko3SVlxNnhTUHR5aWVLa3Z1STd6RC1ZbkxlbkJRVGFqVmVVSjVfclNiR3lkZGc1UUhITDNJMHJlRkNUVkJyaHk3cVQtYXZoUU9JZjZ2TXpiLVZJQXg3c19OOFdnUDZrcGRVOHRrNjJaMmtoLWtRYkNuREIyYVhVX1dSZjlNamJIM0RjUUlHRFpiUFN5cTAxU0ZZalRUT3cyMG9Kc3ZuUmlOcXo3OTlXNFZqTnJORVNtTFZFcldmTEtfX0U4eEFYYVBCTDc4amJEY1ZZNTZtcFl6b2dsOHNNUG9Ba1AzUFFUQjZVbW54RHBxdGF4eElyN2RqWjd1bXNFY1pGcnVQdEVWRVR5SnRMcE1KRnFFa1I1bUtvVTZ2ckxBNF8tcHVYVUtJU0taUlJNVW9TWHJwVl93?oc=5","date":"2025-03-04","type":"trial","source":"GlobeNewswire","summary":"Dopamine Receptor Antagonists Clinical Trial Pipeline - GlobeNewswire","headline":"Dopamine Receptor Antagonists Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQcTNpSnUxYzFueDF5VkF5RFcwVkhWNU9KLVBGRW5BdnBvbGRCQVBZWk82VFdWRkZ3YnROWmxjS0twQzd5MHJORmFQRTEwQlI1S0JkaEdiSnJlb3QxaWRtajFFUVl6UkE3VjRlekx2dm90Z3FDVWN2RTRkdVlCMXZPcVQ4bDhCeDlPYmtsOWJJdjJNRFRnQk96OGpxc1FTZ0E?oc=5","date":"2025-02-26","type":"regulatory","source":"The Pharma Letter","summary":"Emalex Biosciences’ lead candidate Phase III win in Tourette syndrome - The Pharma Letter","headline":"Emalex Biosciences’ lead candidate Phase III win in Tourette syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNZndkREpOcVJGd1ItT0lBZzJRQ2ZKZDVURmN6V3FiekdmUEJFeUtheDNyTVRqczd0UmctRFBQajZhTjF0NTMtU253M3FJZERlTDNoVzJ4YVE2UDg3czdlRVRYZjRsOVhwMVRCT09iTF85UnM4U0hBeFROTnRFUjFfZzJuSzdpWlpodVdzNmxZNGp3dGJldV8ycnlQQWxfNElxY3VmdGh2T1JPSTVzRVVxb0NqQVBQNkI0ZEVLWHhEd185SGU0b0NjR2hBeVdVc3NJX1B0S1BwVVh4RzhoeTFKS3NIazM3eUpaUm9MeFp2T0pJMlNiMEE?oc=5","date":"2025-02-25","type":"regulatory","source":"Business Wire","summary":"Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study - Business Wire","headline":"Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE0teXhkdXJKTHBzLTJ3TVo5Mjd4b0hNUTJHMTJXLUU4TmJ6a2hFQ3NiaEl2cXlDMS03dlNoYUNaYjZadExfUXRQcDM4cG1tOUZSVHRYM2I5ckRrZ0tnLTU4QlNpd01XcjRNWkxxaVJTWl9IaE0?oc=5","date":"2024-02-28","type":"pipeline","source":"Built In Chicago","summary":"9 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene - Built In Chicago","headline":"9 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQSkEtdTFpQ1R4MU4xRDFEdDlBTTVGRENBR1VLZGV2dFc5dkhQYV9nSDQ0OGk4ekltd1JtRzIwWlBTYU1QeG5UTUpOekhUbFJia2VGS1NPSFUyZFlzeVFCVE9oV0Z1TWVQVGVORnVLOVZzN092NDY2Q3lfajdJX0pJWlFkU2hmczBCSDJJS2p1b3dsQ1I5QlpSb1Jn?oc=5","date":"2023-05-01","type":"regulatory","source":"Pharma Voice","summary":"Emalex aims at a first-in-class breakthrough for Tourette syndrome - Pharma Voice","headline":"Emalex aims at a first-in-class breakthrough for Tourette syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNeW1DTTZKR3ZZT3MwTEgxU2d3MUFDclVnTy0zd2FlWkRkR0lDa2h6M3NDX2tXS0x4VVdoXzFvRE1SWHdDN2tHR2FEcVM1Wi1iWmVFdkJlaGpYUDByTVM3M0xWb2c5Yk5LSWtJZWhMUGg1MmF3NVpRM1VIbDhzWXNnSmlwUnV0eXZDUXFB?oc=5","date":"2023-01-05","type":"trial","source":"globaldata.com","summary":"Tourette Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update - globaldata.com","headline":"Tourette Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNVXhrY2FlWkxXTERPOFpkOEFYcEtHMklWOHBzYkU0V0dHbHhpX3dfeGkyZG04SXlGQl9YV1pkOVhvRUhSdjU2U1Z2MmNTS0hPTDNoRGM4dEU3MVBFMGRWUno0MzAxMzRZeDF2ODhPYm8xNnFKMHBSR3BxTVJ3VkNtT2JDVDRJR2YzRVREbWtyYjBNVzQ0cVZ4OWR0NlItVXpOSV9Wc1Y5RWVlVnR3?oc=5","date":"2022-11-03","type":"regulatory","source":"MedCity News","summary":"Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug - MedCity News","headline":"Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMkh0d0JDdnlVSkZ4Y1lJVFFwUWNoVlNhWWU1cGFCRVFlX0twWTZUMnFYU1BHQVE5LVRLMmY3dWgwd3B5aEpoOVdzZHlTa3otMDdMdXplSDJUNldEZnlHYkhuMmxsRFpuWmNyeUpQQzhvbTRjdDN3ZG1TVVk4Z1hLa1hEeFlLVlBsVU56eDZKSmlDN3Jx?oc=5","date":"2022-07-29","type":"trial","source":"globaldata.com","summary":"Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPbWJhRWNzcmZVQXR6MXRXRERlMDRLRHJ3SWh5YVYxLXNYRVlFRzRCUlpBUDVJanJxZlU3REpZdVNXejFUNnhNZlp1SzVwTUNLVUZkdW9GNnFMOTJ0MF9mQ1FOTmQ5Vk55cmVjYkE3MWZybWtEYnotOTUyUlNHV1N3MUlwVTNDSXVVR21kUEY0SXFUZUNYNDItVGlLbFRMdkFlaHphMzY2ZDJxMV9XZTBSdnhsZHJtak44dktWd1ZyQ0x4cFVSYnJFTlEwZDloQXNkOThiTkJsTk9oTW5zeF9hLUFhLVJpLUVwNUNCbi03OE5MNW9IWl9jRHlR?oc=5","date":"2018-08-14","type":"regulatory","source":"PR Newswire","summary":"Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome - PR Newswire","headline":"Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}